BioMarin Pharmaceutical Earnings & Forecasts

BioMarin Pharmaceutical (BMRN) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 6, 2026	$1.20	$0.92	30.4 %
Q1	May 4, 2026	$0.76	$0.89	-14.6 %
Q4	Feb 23, 2026	$0.46	$0.36	27.8 %
Q3	Oct 27, 2025	$0.12	$0.51	-76.5 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 6, 2026	$990.00M	$931.29M	6.30 %
Q1	May 4, 2026	$766.21M	$754.59M	1.54 %
Q4	Feb 23, 2026	$875.00M	$832.88M	5.06 %
Q3	Oct 27, 2025	$776.13M	$781.89M	-0.74 %

BioMarin Pharmaceutical Guidance

BioMarin Pharmaceutical (BMRN)은 지난 8월 6, 2026에 fiscal year 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $4.9 - $5.1 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $4.8보다 높은 수치입니다. BioMarin Pharmaceutical는 또한 해당 기간의 매출을 $3.88B - $3.92B 범위로 전망했습니다.

이전 가이던스와 비교하여 BioMarin Pharmaceutical는 주당순이익(EPS) 전망치를 이전 범위인 상향 조정됨에서 $4.85 - $5.05로 상향 조정했습니다. 매출 측면에서는 회사가 매출 전망치를 이전 범위인 유지됨에서 $3.83B - $3.92B로 상향 조정했습니다.

BioMarin Pharmaceutical은 20과 10월 26, 2022 사이에 8월 6, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 11 times and lowered it 2 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.92	$0.89	$0.36	$0.51
Actual	$1.20	$0.76	$0.46	$0.12
Surprise	+30.4%	-14.6%	+27.8%	-76.5%
Revenue
Estimate	$931.3M	$754.6M	$832.9M	$781.9M
Actual	$990.0M	$766.2M	$875.0M	$776.1M
Surprise	+6.30%	+1.54%	+5.06%	-0.74%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$1.35	$1.72	$1.29	$1.40
Revenue
Consensus	$1.03B	$1.12B	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B Est

BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925

Benzinga Newsdesk

PRO
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over earnings of $1.44 per share

Benzinga Newsdesk

PRO
BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.95-$5.15 to $4.85-$5.05 vs $4.43 Est; Raises FY2026 Sales Guidance from $3.325B-$3.425B to $3.825B-$3.925B vs $3.635B Est

Benzinga Newsdesk

BioMarin Pharmaceutical Inc